CCR5 Antagonists (Maraviroc and Vicriviroc) CCR5 antagonists block viral binding to the CCR5 chemokine coreceptor. Several CCR5 antagonists have been tested in clinical trials. In August 2007, maraviroc was approved for use in multidrug-resistant patients with R5-only virus. A phase IIb/III trial of this agent in treatment-experienced patients has been reported.[4,5] A phase IIb/III study …
These are some contacts Silikon 1000 : https://www.derekjones.com or www.resderm.com or https://www.orentreich.com/ (use off label in the US) Bioalcamid in Canada (several cities) https://www.faceforward.ca/ or Mexico (monterrey)egarzaskin@yahoo.com (not FDA approved in the US yet) PMMA in Mexico (tijuana) luis_casavantes@msn.com ( product approved in the US: Artefill, but very expensive!) Sculptra : https://sculptra.com/US/Index.jsp (FDA approved for …
Facial Reconstruction Options in the Us- Sept 2007 Read More »
The Georgetown University Health Policy Institute has written A CONSUMER GUIDE FOR GETTING AND KEEPING HEALTH INSURANCE for each state and the District of Columbia — fifty-one in all. These Consumer Guides are available at this web site and will be updated periodically as changes in federal and state policy warrant. https://healthinsuranceinfo.net/ I hear this …
Health Insurance Resources for HIV Positive People (non ADAP) Read More »
The New Wave of HIV Drugs is Here For the first time in 10 years, HIV+ patients will have access to two new HIV drug classes. Patients with ongoing viral replication that have been failing current medicines will have a “second chance” to control their HIV by starting new drugs to which their virus has …
Positively Aware July/August 2007You’re Fired!Changing your doctor by Matt Sharp Donald Trump’s irritating voice rang in my ears as I stormed home from one of the most humiliating experiences as a “patient” in my 20 years of receiving HIV care. The details of the situation are not as important as the light bulb that went …
I am seeing a very strong trend of allowing pharmaceutical employees to speak to clinician and patient groups about their products in lectures set up by industry. I have attended many CME based and non CME lectures and I can say that I have hardly seen a neutral or unbiased lecture when a pharma employee …
Should pharmaceutical employees be allowed to lecture about their products? Read More »
Paul Bellman is one of the most concerned doctors in the US on the subject of how to rescue HIV patients who have ran out of options. Here is a manuscript he wrote for patients and medical students on the subject that I highly recommend for all to read: https://salvagetherapies.org/articals/salvageTreatment_ManualDrBellmanAug07.pdf
This study really worries me. Median CD4 cells were in the 400, and half were naive. So these are not sick patients. I wish they had defined what mild cognitive impairment is. I forget faces, names, things to do, sometimes important personal data, etc. At 48 years old, I have the feeling that this is …
If you are thinking about obtaining TMC 125 (Etravirine, a new non nucleoside yet to be approved) via Tibotec’s expanded access program (EAP) and you have developed resistance to non nucleosides in the past (Sustiva, Viramune, Rescriptor), be aware that it is very difficult to know if TMC 125 will work for your virus since …
Be Aware of TMC 125 (Etravirine, Tibotec new non nucleoside) limitations Read More »
The End of Nandrolone Nelson Vergel, Program for Wellness Restoration https://www.gmhc.org/health/treatment/ti/ti21_1.html The current terrain for wasting patients in the era of HAART On March 20, 2007, Watson Laboratories stopped the production of nandrolone decanoate (old brand name: Deca Durabolin), a low-cost injectable anabolic steroid used for HIV wasting, citing the lack of raw-material suppliers for …
I was concerned this would happen. The FDA did not think that the benefits in decreasing visceral fat in HIV positive people outweigh the risks of diabetes, joint pains and hyperglycemia. However, I know this drug works very effectively to decrease belly fat. The problem is that the fat returns when you get off the …
TITAN & DUET Studies COMMENTARY No patient left behind-better treatments for resistant HIV infection The Lancet July 7, 2007 Bernard Hirschel a and Thomas Perneger ba. Division of Infectious Diseases, Geneva University Hospital, Geneva 1211, Switzerlandb. Clinical Epidemiology Service, Geneva University Hospital, Geneva, Switzerland Darunavir (TMC114) is a protease inhibitor specifically designed for “resistance to …
TITAN and DUET Studies from Tibotec- Commentaries in the Lancet Read More »
